A pilot tolerability and efficacy trial of sodium oxybate in ethanol-responsive movement disorders.
Identifieur interne : 001296 ( Ncbi/Merge ); précédent : 001295; suivant : 001297A pilot tolerability and efficacy trial of sodium oxybate in ethanol-responsive movement disorders.
Auteurs : Steven J. Frucht [États-Unis] ; Yvette Bordelon ; William H. Houghton ; Dayton ReardanSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2005.
English descriptors
- KwdEn :
- Adjuvants, Anesthesia (adverse effects), Adjuvants, Anesthesia (therapeutic use), Adult, Aged, Central Nervous System Depressants (adverse effects), Central Nervous System Depressants (therapeutic use), Drug Administration Schedule, Drug Therapy, Combination, Dystonia (diagnosis), Dystonia (drug therapy), Essential Tremor (diagnosis), Essential Tremor (drug therapy), Ethanol (adverse effects), Ethanol (therapeutic use), Female, Humans, Male, Myoclonus (diagnosis), Myoclonus (drug therapy), Pilot Projects, Severity of Illness Index, Sodium Oxybate (adverse effects), Sodium Oxybate (therapeutic use), Treatment Outcome.
- MESH :
- chemical , adverse effects : Adjuvants, Anesthesia, Central Nervous System Depressants, Ethanol, Sodium Oxybate.
- chemical , therapeutic use : Adjuvants, Anesthesia, Central Nervous System Depressants, Ethanol, Sodium Oxybate.
- diagnosis : Dystonia, Essential Tremor, Myoclonus.
- drug therapy : Dystonia, Essential Tremor, Myoclonus.
- Adult, Aged, Drug Administration Schedule, Drug Therapy, Combination, Female, Humans, Male, Pilot Projects, Severity of Illness Index, Treatment Outcome.
Abstract
Sodium oxybate is currently approved in the United States exclusively for the treatment of cataplexy in narcoleptic patients. In a prior article published in this journal, we reported a patient with severe posthypoxic myoclonus whose myoclonus improved with ethanol and also with treatment with sodium oxybate. We extend this preliminary observation to five other patients with ethanol-responsive movement disorders in an open-label, dose-titration, add-on, 8-week trial. All five patients (one with severe alcohol-responsive posthypoxic myoclonus, two with epsilon-sarcoglycan-linked myoclonus-dystonia, and two with essential tremor) experienced improvement from baseline of 50% or greater as measured by blinded videotape review. Tolerability was satisfactory, with dose-dependent sedation as the most common side effect. Further studies of this drug in hyperkinetic movement disorders are warranted.
DOI: 10.1002/mds.20605
PubMed: 15986420
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 003016
- to stream PubMed, to step Curation: 003016
- to stream PubMed, to step Checkpoint: 003257
Links to Exploration step
pubmed:15986420Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">A pilot tolerability and efficacy trial of sodium oxybate in ethanol-responsive movement disorders.</title><author><name sortKey="Frucht, Steven J" sort="Frucht, Steven J" uniqKey="Frucht S" first="Steven J" last="Frucht">Steven J. Frucht</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, Columbia University Medical Center, New York, New York 10032, USA. sf216@columbia.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Columbia University Medical Center, New York, New York 10032</wicri:regionArea><wicri:noRegion>New York 10032</wicri:noRegion></affiliation></author><author><name sortKey="Bordelon, Yvette" sort="Bordelon, Yvette" uniqKey="Bordelon Y" first="Yvette" last="Bordelon">Yvette Bordelon</name></author><author><name sortKey="Houghton, William H" sort="Houghton, William H" uniqKey="Houghton W" first="William H" last="Houghton">William H. Houghton</name></author><author><name sortKey="Reardan, Dayton" sort="Reardan, Dayton" uniqKey="Reardan D" first="Dayton" last="Reardan">Dayton Reardan</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2005">2005</date><idno type="doi">10.1002/mds.20605</idno><idno type="RBID">pubmed:15986420</idno><idno type="pmid">15986420</idno><idno type="wicri:Area/PubMed/Corpus">003016</idno><idno type="wicri:Area/PubMed/Curation">003016</idno><idno type="wicri:Area/PubMed/Checkpoint">003257</idno><idno type="wicri:Area/Ncbi/Merge">001296</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">A pilot tolerability and efficacy trial of sodium oxybate in ethanol-responsive movement disorders.</title><author><name sortKey="Frucht, Steven J" sort="Frucht, Steven J" uniqKey="Frucht S" first="Steven J" last="Frucht">Steven J. Frucht</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, Columbia University Medical Center, New York, New York 10032, USA. sf216@columbia.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Columbia University Medical Center, New York, New York 10032</wicri:regionArea><wicri:noRegion>New York 10032</wicri:noRegion></affiliation></author><author><name sortKey="Bordelon, Yvette" sort="Bordelon, Yvette" uniqKey="Bordelon Y" first="Yvette" last="Bordelon">Yvette Bordelon</name></author><author><name sortKey="Houghton, William H" sort="Houghton, William H" uniqKey="Houghton W" first="William H" last="Houghton">William H. Houghton</name></author><author><name sortKey="Reardan, Dayton" sort="Reardan, Dayton" uniqKey="Reardan D" first="Dayton" last="Reardan">Dayton Reardan</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="2005" type="published">2005</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adjuvants, Anesthesia (adverse effects)</term><term>Adjuvants, Anesthesia (therapeutic use)</term><term>Adult</term><term>Aged</term><term>Central Nervous System Depressants (adverse effects)</term><term>Central Nervous System Depressants (therapeutic use)</term><term>Drug Administration Schedule</term><term>Drug Therapy, Combination</term><term>Dystonia (diagnosis)</term><term>Dystonia (drug therapy)</term><term>Essential Tremor (diagnosis)</term><term>Essential Tremor (drug therapy)</term><term>Ethanol (adverse effects)</term><term>Ethanol (therapeutic use)</term><term>Female</term><term>Humans</term><term>Male</term><term>Myoclonus (diagnosis)</term><term>Myoclonus (drug therapy)</term><term>Pilot Projects</term><term>Severity of Illness Index</term><term>Sodium Oxybate (adverse effects)</term><term>Sodium Oxybate (therapeutic use)</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Adjuvants, Anesthesia</term><term>Central Nervous System Depressants</term><term>Ethanol</term><term>Sodium Oxybate</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Adjuvants, Anesthesia</term><term>Central Nervous System Depressants</term><term>Ethanol</term><term>Sodium Oxybate</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Dystonia</term><term>Essential Tremor</term><term>Myoclonus</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Dystonia</term><term>Essential Tremor</term><term>Myoclonus</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Drug Administration Schedule</term><term>Drug Therapy, Combination</term><term>Female</term><term>Humans</term><term>Male</term><term>Pilot Projects</term><term>Severity of Illness Index</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Sodium oxybate is currently approved in the United States exclusively for the treatment of cataplexy in narcoleptic patients. In a prior article published in this journal, we reported a patient with severe posthypoxic myoclonus whose myoclonus improved with ethanol and also with treatment with sodium oxybate. We extend this preliminary observation to five other patients with ethanol-responsive movement disorders in an open-label, dose-titration, add-on, 8-week trial. All five patients (one with severe alcohol-responsive posthypoxic myoclonus, two with epsilon-sarcoglycan-linked myoclonus-dystonia, and two with essential tremor) experienced improvement from baseline of 50% or greater as measured by blinded videotape review. Tolerability was satisfactory, with dose-dependent sedation as the most common side effect. Further studies of this drug in hyperkinetic movement disorders are warranted.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">15986420</PMID><DateCreated><Year>2005</Year><Month>10</Month><Day>11</Day></DateCreated><DateCompleted><Year>2006</Year><Month>02</Month><Day>16</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN><JournalIssue CitedMedium="Print"><Volume>20</Volume><Issue>10</Issue><PubDate><Year>2005</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>A pilot tolerability and efficacy trial of sodium oxybate in ethanol-responsive movement disorders.</ArticleTitle><Pagination><MedlinePgn>1330-7</MedlinePgn></Pagination><Abstract><AbstractText>Sodium oxybate is currently approved in the United States exclusively for the treatment of cataplexy in narcoleptic patients. In a prior article published in this journal, we reported a patient with severe posthypoxic myoclonus whose myoclonus improved with ethanol and also with treatment with sodium oxybate. We extend this preliminary observation to five other patients with ethanol-responsive movement disorders in an open-label, dose-titration, add-on, 8-week trial. All five patients (one with severe alcohol-responsive posthypoxic myoclonus, two with epsilon-sarcoglycan-linked myoclonus-dystonia, and two with essential tremor) experienced improvement from baseline of 50% or greater as measured by blinded videotape review. Tolerability was satisfactory, with dose-dependent sedation as the most common side effect. Further studies of this drug in hyperkinetic movement disorders are warranted.</AbstractText><CopyrightInformation>Copyright (c) 2005 Movement Disorder Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Frucht</LastName><ForeName>Steven J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Columbia University Medical Center, New York, New York 10032, USA. sf216@columbia.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bordelon</LastName><ForeName>Yvette</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Houghton</LastName><ForeName>William H</ForeName><Initials>WH</Initials></Author><Author ValidYN="Y"><LastName>Reardan</LastName><ForeName>Dayton</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000759">Adjuvants, Anesthesia</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002492">Central Nervous System Depressants</NameOfSubstance></Chemical><Chemical><RegistryNumber>3K9958V90M</RegistryNumber><NameOfSubstance UI="D000431">Ethanol</NameOfSubstance></Chemical><Chemical><RegistryNumber>502-85-2</RegistryNumber><NameOfSubstance UI="D012978">Sodium Oxybate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000759">Adjuvants, Anesthesia</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D002492">Central Nervous System Depressants</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004334">Drug Administration Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004359">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004421">Dystonia</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D020329">Essential Tremor</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000431">Ethanol</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009207">Myoclonus</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010865">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012720">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012978">Sodium Oxybate</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>6</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>2</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>6</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="doi">10.1002/mds.20605</ArticleId><ArticleId IdType="pubmed">15986420</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country></list><tree><noCountry><name sortKey="Bordelon, Yvette" sort="Bordelon, Yvette" uniqKey="Bordelon Y" first="Yvette" last="Bordelon">Yvette Bordelon</name><name sortKey="Houghton, William H" sort="Houghton, William H" uniqKey="Houghton W" first="William H" last="Houghton">William H. Houghton</name><name sortKey="Reardan, Dayton" sort="Reardan, Dayton" uniqKey="Reardan D" first="Dayton" last="Reardan">Dayton Reardan</name></noCountry><country name="États-Unis"><noRegion><name sortKey="Frucht, Steven J" sort="Frucht, Steven J" uniqKey="Frucht S" first="Steven J" last="Frucht">Steven J. Frucht</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001296 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 001296 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:15986420
|texte= A pilot tolerability and efficacy trial of sodium oxybate in ethanol-responsive movement disorders.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:15986420" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |